Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors

B. A. Silver; A. L. Barlock; M. E. Lippman; T. Anderson; R. I. Fisher

Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors

B. A. Silver, A. L. Barlock, M. E. Lippman, T. Anderson, R. I. Fisher

Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

We have conducted a broad phase II clinical trial a chlorozotocin in 74 patients including 28 with malignant melanoma, 18 with breast cancer, nine with non-Hodgkin's lymphoma, six with nonseminomatous testicular cancer, five with ovarian cancer, four with sarcoma, three with non-beta islet cell carcinoma of the pancreas, and one with anaplastic carcinoma of the thyroid. Objective responses were noted only in 15% of the patients with melanoma and in 11% of the patients with non-Hodgkin's lymphoma. Significant leukopenia and thrombocytopenia were observed only in previously treated patients. Chlorozotocin does not appear to offer clinically significant advantages over other currently available nitrosoureas.

Original language	English (US)
Pages (from-to)	1229-1230
Number of pages	2
Journal	Cancer Treatment Reports
Volume	66
Issue number	5
State	Published - Sep 20 1982

ASJC Scopus subject areas

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors'. Together they form a unique fingerprint.

Cite this

@article{99a5809113654296a90022611805f573,

title = "Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors",

abstract = "We have conducted a broad phase II clinical trial a chlorozotocin in 74 patients including 28 with malignant melanoma, 18 with breast cancer, nine with non-Hodgkin's lymphoma, six with nonseminomatous testicular cancer, five with ovarian cancer, four with sarcoma, three with non-beta islet cell carcinoma of the pancreas, and one with anaplastic carcinoma of the thyroid. Objective responses were noted only in 15% of the patients with melanoma and in 11% of the patients with non-Hodgkin's lymphoma. Significant leukopenia and thrombocytopenia were observed only in previously treated patients. Chlorozotocin does not appear to offer clinically significant advantages over other currently available nitrosoureas.",

author = "Silver, {B. A.} and Barlock, {A. L.} and Lippman, {M. E.} and T. Anderson and Fisher, {R. I.}",

year = "1982",

month = sep,

day = "20",

language = "English (US)",

volume = "66",

pages = "1229--1230",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors

AU - Silver, B. A.

AU - Barlock, A. L.

AU - Lippman, M. E.

AU - Anderson, T.

AU - Fisher, R. I.

PY - 1982/9/20

Y1 - 1982/9/20

N2 - We have conducted a broad phase II clinical trial a chlorozotocin in 74 patients including 28 with malignant melanoma, 18 with breast cancer, nine with non-Hodgkin's lymphoma, six with nonseminomatous testicular cancer, five with ovarian cancer, four with sarcoma, three with non-beta islet cell carcinoma of the pancreas, and one with anaplastic carcinoma of the thyroid. Objective responses were noted only in 15% of the patients with melanoma and in 11% of the patients with non-Hodgkin's lymphoma. Significant leukopenia and thrombocytopenia were observed only in previously treated patients. Chlorozotocin does not appear to offer clinically significant advantages over other currently available nitrosoureas.

AB - We have conducted a broad phase II clinical trial a chlorozotocin in 74 patients including 28 with malignant melanoma, 18 with breast cancer, nine with non-Hodgkin's lymphoma, six with nonseminomatous testicular cancer, five with ovarian cancer, four with sarcoma, three with non-beta islet cell carcinoma of the pancreas, and one with anaplastic carcinoma of the thyroid. Objective responses were noted only in 15% of the patients with melanoma and in 11% of the patients with non-Hodgkin's lymphoma. Significant leukopenia and thrombocytopenia were observed only in previously treated patients. Chlorozotocin does not appear to offer clinically significant advantages over other currently available nitrosoureas.

UR - http://www.scopus.com/inward/record.url?scp=0019946644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019946644&partnerID=8YFLogxK

M3 - Article

C2 - 6211231

AN - SCOPUS:0019946644

VL - 66

SP - 1229

EP - 1230

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

ER -